The Impact Of Cancer Drugs Fund Reforms On Reimbursement Of Oncology Drugs In The UK

Abstract

As the average life expectancy of Koreans increases, the prevalence of prostate cancer (Pca) is increasing in men aged 70 years or older. But, in the absence of pattern data of primary treatment for elder patients was unable to health care policy for prostate cancer. This study aims to examine the medical patterns of major for prostate cancer. MethOds: The treatment patterns of Pca were analyzed by using the linked data of the Korea Central Cancer Registry and National Health Insurance Service (NHIS), using International Classification of Diseases, 10th diagnosis codes. To analyze the status of medical use of Pca, the database of NHIS claims in 2002-2014 was used. The treatment pattern due to Pca were investigated according to year based on the details of age, insurance type, primary treatment type, hospital type, comorbidity and cancer stage. Results: Overall 71,223 patients were identified and 45,197 new medical users were selected. In terms of the stage of cancer, the proportion of 'Localized' group increased from 46% in 2005 to 58% in 2013. Patients that the Charlson's Comorbidity Index is 1 point at the time of the first diagnosis had the most proportion at 26.78%, and the proportion of 4 points or more tended to increase annually for 11 years from 2003 to 2013. However, there was a continuous increasing trend in surgery (including robot surgery) from 23.7% in 2003 to 48.5% in 2013. Among those who received hormone therapy as a first treatment in patients aged 75-79 increased annually from 20.8% in 2003 to 27.3% in 2013, and patients aged 80 or more tended to increase. cOnclusiOns: Considering the increased prevalence of elder patients with Pca, it is important to understand the real-world status of medical treatment and to generate evidence for support decision-making of national health policy in Korea.

Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland

“…In Germany, no HTA reports were available before the introduction of the current HTA system (AMNOG) in 2011 [ 42 ]. In England, reforms of NICE approval timelines along with the Cancer Drug Fund (CDF), require all HTA submissions to be processed within 90 days of EMA approval [ 43 ]. Introduction of the CDF may impact launch decisions, HTA outcomes, list prices, and economic and clinical restrictions.…”